169 related articles for article (PubMed ID: 18294295)
1. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
2. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
3. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
[TBL] [Abstract][Full Text] [Related]
4. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
[TBL] [Abstract][Full Text] [Related]
5. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
[TBL] [Abstract][Full Text] [Related]
6. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
[TBL] [Abstract][Full Text] [Related]
7. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Sone K; Oguri T; Uemura T; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
BMC Cancer; 2019 Mar; 19(1):246. PubMed ID: 30890141
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
12. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
13. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
[TBL] [Abstract][Full Text] [Related]
14. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Jabir RS; Ho GF; Annuar MABA; Stanslas J
Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
[TBL] [Abstract][Full Text] [Related]
15. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension
.
Pei Q; Yang L; Tan HY; Liu SK; Liu Y; Huang L; Li RH; Wan Q; Huang J; Guo CX; Zuo XC; Li J; Yang GP
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):659-665. PubMed ID: 28518053
[TBL] [Abstract][Full Text] [Related]
16. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
17. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
Srinivasan Y; Sasa M; Honda J; Takahashi A; Uno S; Kamatani N; Kubo M; Nakamura Y; Zembutsu H
Pharmacogenet Genomics; 2011 Sep; 21(9):552-8. PubMed ID: 21799462
[TBL] [Abstract][Full Text] [Related]
19. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
